Jebinta Cusub
Shirkad Israa’iili ah oo ka shaqaysa AI, Converge Bio, ayaa uruursatay $25M si ay u beddesho daahfurka dawooyinka
Shirkad Israa'iili ah oo sameysa AI oo la yiraahdo Converge Bio ayaa heshay maalgelin $25 milyan oo doolar oo ah Series A, taasoo ka dhigaysa wadarta $30M ee madal ay ku sahaminayso dawooyinka oo ay isticmaalayso AI.
Yeruusaalem, 13 Janaayo, 2026 (TPS-IL) — Shirkad cusub oo Israa’iili ah oo lagu magacaabo converge bio ayaa heshay $25 milyan oo doolar oo ah wareegga Series A oo ay hoggaaminayso Bessemer Venture Partners, taasoo ka dhigaysa maalgelinteeda guud $30 milyan. Shirkadda Converge oo la aasaasay 2024, waxay horumarisaa madal AI ah oo dardargelisa helitaanka daawooyinka shirkadaha Biotech iyo Pharmaceutical, iyadoo bixisa qalabka aqoonsiga bartilmaameedka, naqshadaynta antibody-ga, iyo hagaajinta borotiinka.
Madalku waxa uu mar horeba isticmaalayaa in ka badan toban shirkadood oo caalami ah, waxana uu keenayaa natiijooyin la cabbiri karo cilmi-baarista kansarka, cudurrada difaaca jirka, iyo cudurrada neerfaha. Madaxa Shirkadda (CEO) Dov Gertz waxa uu sheegay in ujeedadu tahay in “shirkad kasta oo Biotech iyo Pharma ay noqoto shirkad AI ah.
